Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)

Well, a $1 billion acquisition, not so unusual in the life sciences industry arena...

…but, in fact, quite rare!

Let's consider this: a Phase II candidate… in an "ultra-rare" indication, Hypophosphatasia (< 1/100.000 prevalence according to Orphanet).. $1 billion... the largest, largest ever deal in orphan diseases.. for a single drug candidate.

Humm…this is all good BUT what if the actual driver in this acquisition is in fact a far larger, blockbuster-type underlying indication such as…osteoporosis? 

Well, just an idea! 

Websites:

Alexion Pharmaceuticals

Enobia Pharma